Summary of REACH and CLL8 clinical outcome with PTK2 expression
| Study description summary . | REACH . | CLL8 . |
|---|---|---|
| R-FC vs FC in second-line CLL . | R-FC vs FC in first-line CLL . | |
| ITT (R-FC vs FC) | HR = 0.65 (30.6 mo vs 20.6 mo), n = 552 (290 PFS events) | HR = 0.56 (51.8 mo vs 32.8 mo), n = 817 |
| Biomarker population with PTK2 gene expression data (R-FC vs FC, PFS) | HR = 0.68 (30.3 mo vs 18.5 mo), n = 300 (156 PFS events) | HR = 0.54 (55.4 mo vs 29.9 mo), n = 282 (172 PFS events) |
| HR of R-FC vs FC in PTK2 low/high subgroups (median cutoff) | 0.94 (20 mo vs 17.9 mo)/0.48 (NA vs 21.5 mo) | 0.6 (45.1 mo vs 32.3 mo)/0.42 (61 mo vs 28.3 mo) |
| HR of PTK2 high vs PTK2 low (median cutoff) in FC/R-FC | 0.86/0.46 | 1.08/0.75 |
| Study description summary . | REACH . | CLL8 . |
|---|---|---|
| R-FC vs FC in second-line CLL . | R-FC vs FC in first-line CLL . | |
| ITT (R-FC vs FC) | HR = 0.65 (30.6 mo vs 20.6 mo), n = 552 (290 PFS events) | HR = 0.56 (51.8 mo vs 32.8 mo), n = 817 |
| Biomarker population with PTK2 gene expression data (R-FC vs FC, PFS) | HR = 0.68 (30.3 mo vs 18.5 mo), n = 300 (156 PFS events) | HR = 0.54 (55.4 mo vs 29.9 mo), n = 282 (172 PFS events) |
| HR of R-FC vs FC in PTK2 low/high subgroups (median cutoff) | 0.94 (20 mo vs 17.9 mo)/0.48 (NA vs 21.5 mo) | 0.6 (45.1 mo vs 32.3 mo)/0.42 (61 mo vs 28.3 mo) |
| HR of PTK2 high vs PTK2 low (median cutoff) in FC/R-FC | 0.86/0.46 | 1.08/0.75 |
NA, not assessed.